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thelial voltage that facilitates proton secretion by neighbor-
ing intercalated cells. This indirect coupling of sodium reab-
sorption and proton secretion is thought to underlie the 
fludrocortisone-furosemide test for maximal urinary acidifi-
cation in patients with suspected distal renal tubular acido-
sis. In patients with CKD, acidosis-induced aldosterone may 
contribute to progression of kidney disease. In summary, al-
dosterone is a powerful regulator of renal acid excretion re-
quired for normal acid-base balance.  © 2014 S. Karger AG, Basel
 Introduction
 Systemic acid-base homeostasis is maintained and 
controlled by the concerted action of various organs in-
cluding lungs, kidneys, liver, bone, skeletal muscle, and 
intestine. Among them, lungs and kidneys play arguably 
the most important role as evident from respiratory dis-
orders and inherited or acquired renal diseases.
 Daily metabolism in an adult healthy person with stan-
dard diet and average physical activity produces approxi-
mately 1 mmol of protons per kilogram body weight 
which must be buffered or eliminated. Elimination and 
buffering of protons critically depend on the kidney. Ap-
proximately 20 mmol of acid are absorbed from diet and 
an additional 10 mmol base equivalents are lost due to 
intestinal secretions. The major acid load comes from 
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 Abstract 
 Aldosterone is classically associated with the regulation of 
salt and potassium homeostasis but has also profound ef-
fects on acid-base balance. During acidosis, circulating aldo-
sterone levels are increased and the hormone acts in concert 
with angiotensin II and other factors to stimulate renal acid 
excretion. Pharmacological blockade of aldosterone action 
as well as inherited or acquired syndromes of impaired aldo-
sterone release or action impair the renal response to acid 
loading and cause hyperkalemic renal tubular acidosis. The 
mineralocorticoid receptor (MR) mediating the genomic ef-
fects of aldosterone is expressed in all cells of the distal 
nephron including all subtypes of intercalated cells. In acid-
secretory type A intercalated cells, aldosterone stimulates 
proton secretion into urine, whereas in non-type A interca-
lated cells, aldosterone increases the activity of the luminal 
anion exchanger pendrin stimulating bicarbonate secretion 
and chloride reabsorption. Aldosterone has also stimulatory 
effects on proton secretion that may be mediated by a non-
genomic pathway. In addition, aldosterone indirectly stimu-
lates renal acid excretion by enhancing sodium reabsorption 
through the epithelial sodium channel ENaC. Increased so-
dium reabsorption enhances the lumen-negative transepi-
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daily metabolism liberating around 15,000 mmol of vola-
tile acid in the form of CO 2  that are eliminated by ventila-
tion and 40 mmol of non-volatile acids that require im-
mediate buffering (mostly by bicarbonate) or direct renal 
excretion. The kidney contributes to buffering of acids by 
reabsorbing virtually all filtered bicarbonate and the de 
novo synthesis of bicarbonate from ammoniagenesis 
leading to the excretion of approximately 40 mmol of am-
monium into urine. Additionally, the kidneys excrete free 
protons that have to be buffered by urinary buffers, so-
called titratable acids (mostly phosphate), thereby buffer-
ing and eliminating a total of 70 mmol acid/day  [1, 2] .
 The different nephron segments specifically contrib-
ute to the control of acid-base homeostasis by the kidney 
 [1, 3, 4] . Proximal tubule segments are involved in bicar-
bonate reabsorption, ammoniagenesis, and determina-
tion of urinary excretion of titratable acids, the thick as-
cending limb of the loop of Henle (TAL) mostly reabsorbs 
bicarbonate, and the collecting ducts excrete protons and 
ammonium and are the major site of adapting and fine-
tuning renal acid-base excretion  [4] .
 Whether the proximal tubule and the thick ascending 
limb are directly regulated by aldosterone is controver-
sial, whereas the functions of the distal convoluted tubule 
(DCT), connecting tubule and collecting duct system, 
collectively referred to as aldosterone sensitive distal 
nephron (ASDN), are directly and indirectly modulated 
by aldosterone  [5–7] .
 Reabsorption of bicarbonate in the proximal tubule is 
mediated by the secretion of protons into primary urine 
by Na + /H +  exchangers (NHEs) and proton pumps situ-
ated in the apical brush border membrane  [8] . NHE3
(SLC9A3) is the major NHE isoform in adults  [9] . NHE3 
contributes also as a major mechanism to sodium reab-
sorption in the proximal tubule. Protons for NHEs and 
proton pumps are generated by intracellular carbonic an-
hydrases (mostly carbonic anhydrase II, CAII)  [8] . The 
secreted protons combine in the luminal fluid with fil-
tered bicarbonate to form carbon dioxide (CO 2 ) and wa-
ter (H 2 O). This reaction is catalyzed by membrane-an-
chored extracellular carbonic anhydrases (mostly car-
bonic anhydrase IV, CAIV)  [8] . CO 2  diffuses into 
proximal tubule cells. Bicarbonate formed by rehydration 
of CO 2  by intracellular carbonic anhydrases leaves proxi-
mal tubular cells across the basolateral cell membrane 
into blood via the electrogenic Na + -HCO 3  cotransporter 
NBCe1 (SLC4A4)  [10] . Another part of bicarbonate reab-
sorption occurs through the paracellular pathway due to 
solvent drag driven by the lumen-negative potential and 
the osmotic gradient built by active solute transport  [8] .
 Bicarbonate not reabsorbed by the proximal tubule is 
reabsorbed in the TAL and the DCT. Thus, urine entering 
the collecting duct system contains only minute amounts 
of bicarbonate under conditions of acid-base balance. 
The mechanisms mediating bicarbonate reabsorption in 
the TAL are similar to the proximal tubule involving also 
NHE3 and proton pumps on the luminal membrane  [11] . 
The exit pathways for bicarbonate across the basolateral 
membrane are not well defined. The electroneutral Na + -
HCO 3  cotransporter NBCn1 is localized at the basolat-
eral membrane but is thought to mediate rather bicarbon-
ate uptake from blood required for ammonium reabsorp-
tion by the TAL  [12] .
 The late section of the DCT is characterized by the 
presence of the first intercalated cells, which express lu-
minal proton pumps (V-type H + -ATPases) and the baso-
lateral chloride-bicarbonate exchanger (AE1).
 Ammoniagenesis takes place only in the proximal tu-
bule and serves the elimination of protons and the de 
novo generation of bicarbonate from the metabolism of 
glutamine. Glutamine is extracted from peritubular capil-
laries, in part mediated by the glutamine transporter 
SNAT3 (SLC38A3) at the basolateral membrane of prox-
imal tubule cells  [13, 14] . Glutamine is further imported 
into mitochondria and metabolized by mitochondrial 
phosphate-dependent glutaminases and glutamate de-
hydrogenases to yield α-ketoglutarate. These steps liber-
ate two NH 3  and one bicarbonate ion per glutamine. 
α-Ketoglutarate can then be further metabolized during 
gluconeogenesis or be converted to yield additional two 
HCO 3 –  ions  [2] . The bicarbonate synthesized during am-
moniagenesis is exported via the basolateral NBCe1 bi-
carbonate transporter whereas NH 3  either diffuses into 
urine and is trapped as NH 4 +  after protonation or binds 
intracellularly protons and may be excreted into urine by 
the NHE3 exchanger instead of a proton.
 Most of the ammonium excreted into urine is reab-
sorbed in the TAL by the NKCC2 cotransporter. NH 4 +  is 
accumulated in the interstitium, a process that may re-
quire sulfatides binding ammonium  [15, 16] .
 In the DCT and collecting duct system, at least two 
types of intercalated cells mediate acid or alkali excretion, 
respectively. Type A intercalated cells secrete protons and 
ammonium whereas type B intercalated cells excrete bi-
carbonate  [3] . Type A intercalated cells produce bicar-
bonate from the hydration of CO 2  and the excretion of 
protons by V-type proton pumps (V-ATPases or H + -
ATPases) into urine  [4, 17] . Bicarbonate generation is 
catalyzed by the intracellular carboanhydrase II (CAII). 
The newly formed bicarbonate is secreted into the inter-
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stitium/blood across the basolateral membrane by the
anion exchanger 1 (SLC4A1, AE1)  [4] . Proton secretion 
drives ammonium excretion along the collecting duct. 
Ammonium excretion is mediated by specific transport 
proteins of the rhesus protein family, RhBG and RhCG 
 [4, 15, 18] . RhCG is critical for renal ammonium excre-
tion  [19–21] and upregulated during acidosis  [18] .
 Titratable acids are alkali buffers neutralizing protons 
in urine. The major urinary titratable acids are inorganic 
phosphate (HPO 3 2–  and H 2 PO 3– ) and citrate  [22] . The 
amount of available titratable acids depends mostly on 
their reabsorption in the proximal tubule since both 
phosphate and citrate are freely filtered and actively re-
absorbed to some extent by the proximal tubule. The rate 
of reabsorption of phosphate by its major transporter
NaPiIIa and citrate by NaDC1 is highly pH-sensitive and 
in the case of phosphate reabsorption regulated by vari-
ous hormones and factors  [23–25] . Titratable acids are 
required to buffer protons as proton secretion by proton 
pumps is limited by the inability to pump protons against 
a proton gradient >3.5 pH units (intracellular pH approx. 
7.2 vs. maximal urinary pH 4.5).
 Bicarbonate excretion is mediated by type B and non-
A/non-B intercalated cells that are present in the late 
DCT, CNT, and CCD. These cells express the chloride-
bicarbonate exchanger pendrin (SLC26A4) on the lumi-
nal membrane secreting bicarbonate into urine in ex-
change for urinary chloride  [26, 27] . Pendrin serves also 
chloride reabsorption and blood pressure regulation  [28, 
29] .
 A variety of factors, such as electrolyte status and hor-
mones, influence renal acid-base metabolism and han-
dling. Among them, angiotensin II and aldosterone play 
a very prominent role as discussed below. In addition, 
endothelin is a potent stimulus for renal acid excretion 
and may also enhance aldosterone secretion during aci-
dosis  [30–35] . Also insulin, prostaglandins, norepineph-
rine, glucocorticoids, and many more hormones modu-
late renal acid-base excretion  [1] . This review will focus 
on the role of aldosterone in renal acid-base handling.
 Regulation of Aldosterone by Acid-Base Status
 Aldosterone secretion and levels are elevated during 
acidosis in humans and small and large animal models 
 [36–44] . This increase in aldosterone levels is at least in 
part independent from changes in plasma levels of potas-
sium and occurs even in the presence of a blockade of 
angiotensin II synthesis or action and with suppressed 
ACTH levels, factors known to stimulate aldosterone se-
cretion  [38, 42, 45] .
 TASK1 and TASK3 potassium channels that are very 
sensitive to external pH changes and whose activity is 
suppressed by physiological proton concentrations are 
highly expressed in zona glomerulosa cells and involved 
in the regulation of aldosterone secretion. However, their 
presence in the adrenal gland is not required for the aldo-
sterone secretion stimulated by acidosis  [45] . Thus, the 
acid-sensing mechanism responsible for aldosterone se-
cretion by zona glomerulosa cells remains unknown but 
may reside in these cells as zona glomerulosa cells cul-
tured in vitro are responsive to changes in pCO 2  and pH 
of culture media  [46] .
 Aldosterone-Sensitive Regulation of Acid-Base 
Homeostasis
 Acidosis increases the circulating levels not only of al-
dosterone but also of angiotensin II  [41, 42] . Angiotensin 
II acts on renal acid excretion by stimulating NHE3, 
NBCe1 and H + -ATPase-dependent bicarbonate reab-
sorption as well as ammonium excretion in the proximal 
tubule, and by stimulating H + -ATPase-mediated urinary 
acidification in the collecting duct  [47–51] . Angiotensin 
II may also induce phosphate reabsorption thereby de-
creasing its delivery to the collecting duct and availability 
as buffer. Consequently, blockade of the angiotensin con-
verting enzyme (ACE) or angiotensin II type 1 receptors 
delays the renal adaption to acidosis in healthy humans 
as well as in various animal models  [42, 52–57] .
 Similarly, impaired aldosterone release or signaling af-
fects the ability of the kidney to excrete acid and to re-
spond to an acid load causing hyperkalemic distal renal 
tubular acidosis, also called type IV RTA  [58] . Inhibition 
of aldosterone actions by mineralocorticoid receptor 
(MR) antagonists (e.g. spironolactone, eplerenone) re-
duces renal acid excretion in healthy humans  [42, 59] . 
Also patients with aldosterone deficiency due to adrenal-
ectomy show type IV dRTA which is reversed with aldo-
sterone substitution  [60] . Mutations in the gene CYP11B2 
encoding for the enzyme aldosterone synthase (cortico-
sterone methyloxidase) catalyzing the last steps in the 
synthesis of aldosterone cause hyperreninemic hypoaldo-
steronism with hyperkalemia, low blood pressure, and 
metabolic acidosis  [61] . Also inactivating mutations in 
the MR impairing aldosterone signaling cause similar 
symptoms  [62] .
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 In contrast, syndromes of aldosterone excess cause 
metabolic alkalosis due to inappropriately high acid
excretion  [63] such as in Conn syndrome or syndromes 
of pseudohyperaldosteronism (with the exception of
pseudohypoaldosteronism type II (Gordon syndrome) 
which features metabolic acidosis  [64, 65] ). Mutations in 
CYP11B2 leading to aberrant stimulation by ACTH or 
CYP11B2 gene duplication can cause uncoupled and ex-
cessive aldosterone synthesis in  [66, 67] . More recently, 
mutations in the KCNJ5 potassium channel or the
ATP1A1 (Na + /K + -ATPase α-subunit) and ATP2B3 (a 
Ca 2+ -ATPase) have been found that cause adrenal gland 
adenomas overproducing aldosterone  [68, 69] . In states 
of volume depletion and contraction of the extracellular 
fluid volume, the physiologic increase in aldosterone se-
cretion contributes to the development of metabolic alka-
losis as salt retention by the kidneys is linked to increased 
bicarbonate reabsorption and acid excretion (see also be-
low). The mechanism has been attributed mostly to the 
depletion of chloride  [70] .
 Expression of Key Molecules of the Mineralocorticoid 
Response in Kidney Segments Involved in Acid-Base 
Handling
 The response of the kidney to mineralocorticoids de-
pends on the expression of several key molecules required 
for aldosterone sensitivity and selectivity towards miner-
alocorticoids over glucocorticoids. Mineralocorticoids 
bind to the MR and induce its nuclear translocation where 
the ligand-receptor complex acts as transcription factor. 
Mineralocorticoid over glucocorticoid selectivity is en-
sured by the 11β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2) inactivating 11β-hydroxyglucocorticoids 
and thereby protecting the MR from activation by gluco-
corticoids. At least in rat and mouse kidney, the MR is 
found in the cells lining the TAL, DCT, connecting tubule 
(CNT), and collecting duct system  [5, 71] . In the DCT, 
CNT and CD all cell types, e.g. principal (segment-specif-
ic) cells as well as all subtypes of intercalated cells, express 
the MR. No MR was detected by PCR and immunohisto-
chemistry in proximal tubules and thin limbs of the loop 
of Henle. Similarly, 11β-HSD2 is abundant in the cells of 
the TAL, DCT, CNT and CD but appears not to be ex-
pressed in intercalated cells. Its expression in the rat col-
lecting duct, however, is downregulated during metabol-
ic acidosis  [72] . The glucocorticoid receptor (GR) is 
found in most cells along the entire nephron including 
also all subtypes of intercalated cells. Infusion of aldoste-
rone into adrenalectomized rats induces translocation of 
both GR and MR into the nucleus, suggesting that the GR 
may mediate some effects of aldosterone in MR-negative 
cells. In contrast, corticosterone induces GR and MR 
translocation into the nucleus in all cells, positive or neg-
ative for 11β-HSD2, only at high concentrations whereas 
low doses have no effect on MR translocation in 
11β-HSD2-positive cells  [5] . Thus, glucocorticoids may 
stimulate MR in 11β-HSD2-negative intercalated cells 
and be responsible for some of the effects attributed to 
mineralocorticoids  [71] .
 The MR is phosphorylated at various sites including at 
serine 483, a site that modifies binding of aldosterone and 
glucocorticoids to the receptor. Phosphorylation of S483 
reduces affinity and activation of the receptor. In kidney 
in vivo, most MR is in the non-phosphorylated form ex-
cept in intercalated cells that show a high degree of S483 
phosphorylation  [71] . MR phosphorylation is decreased 
in states of elevated aldosterone such as in volume deple-
tion  [71] . In contrast, in hyperkalemia, MR phosphoryla-
tion is increased and the receptor found mostly in the 
cytoplasm of intercalated cells whereas it is nuclear in 
principal cells. Angiotensin II may play a key role in reg-
ulation of the phosphorylation status of MR in interca-
lated cells and high angiotensin II reduces MR phosphor-
ylation thereby providing a switch in the responsiveness 
of intercalated cells to aldosterone. The effects of angio-
tensin II may in part be mediated by the WNK4 kinase 
and the PP1 phosphatase  [71] .
 The molecules mediating non-genomic rapid effects of 
aldosterone have not been identified to date. Possible 
candidates have been proposed and include GPR30 
(GPER), a membrane-associated estrogen receptor. How-
ever, its role in physiological processes regulated by aldo-
sterone in the kidney remained elusive  [73] .
 Regulation of Renal Acid-Base Transporters by 
Aldosterone
 Regulation of renal acid-base handling by aldosterone 
may occur by direct effects of aldosterone on target cells 
and molecules as well as by indirect effects requiring the 
crosstalk between different cells within a given nephron 
segment or between different nephron segments.
 Direct Regulation
 Genomic Effects of Aldosterone
 Aldosterone stimulates urinary acidification and type 
A intercalated cell function. It may act directly on H + -
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ATPases and AE1 activity  [74–79] . In aldosterone-defi-
cient animals (e.g. due to adrenalectomy and repletion of 
glucocorticoids) urinary ammonium excretion is reduced 
but this may be mostly the result of reduced proton secre-
tion and hyperkalemia impairing proximal ammoniagen-
esis  [78] .
 Treatment of mice with the aldosterone analogue de-
oxycorticosterone acetate (DOCA) or NaHCO 3  alone 
had no effect on the expression of the AE1 anion exchang-
er mRNA and protein abundance  [80] . However, the 
combination of DOCA with NaHCO 3  increased AE1 
mRNA and protein, suggesting a combined action. Simi-
larly, DOCA has no or only very little effects on mRNA 
and protein abundance of H + -ATPases in the collecting 
duct, suggesting that the stimulatory effects of aldoste-
rone on proton secretion must be mediated by other 
mechanisms [Daryadel, Mohebbi, Wagner, unpubl. data]. 
Whether a combined treatment of angiotensin II and al-
dosterone would be able to increase AE1 and H + -ATPase 
abundance has not been directly tested to our knowledge. 
However, infusion of angiotensin II over several days in-
creases protein abundance of the intercalated cell-specif-
ic B1 H + -ATPase subunit  [71] . Moreover, in mice lacking 
the NaCl cotransporter NCC, B1 expression is increased 
and this effect is abolished by either angiotensin receptor 
antagonists or MR blockers, suggesting that the com-
bined action of angiotensin II and aldosterone may be 
required  [71] .
 Similarly, regulation of pendrin in non-type A interca-
lated cells by aldosterone has been described  [81, 82] . 
Whether this effect involves only redistribution of pen-
drin or increased abundance remained open. However, a 
subsequent detailed analysis suggested that DOCA alone 
does not alter pendrin abundance but that a combined 
effect of NaHCO 3  and aldosterone could be observed 
 [80] . Interestingly, expression of pendrin in other tissues 
such as kidney, heart, lung and thyroid gland is stimu-
lated by aldosterone alone  [83] . These in vivo data are in 
contrast to results obtained from in vitro promoter stud-
ies demonstrating reduced pendrin promoter activity 
with aldosterone  [84] . As for the expression of the B1 H + -
ATPase, pendrin expression is regulated by angiotensin 
II  [85] and its expression is sensitive to angiotensin II and 
MR blockers  [71] . 
 Thus, there is mounting evidence for the genomic reg-
ulation of intercalated cell function by aldosterone and 
that complex interactions of aldosterone with angioten-
sin II and possibly further factors are involved. However, 
the exact pathways and the role of the MR in overall in-
tercalated cell function remains to be further explored.
 Non-Genomic Effects of Aldosterone on H + -ATPases
 Aldosterone rapidly stimulates within 5 min H + -
ATPase activity in acid-secretory type A intercalated cells 
of the mouse and human outer medullary collecting duct 
 [75, 76] . Stimulation occurred also in the presence of the 
MR antagonist spironolactone and was thus considered 
to be non-genomic. Moreover, corticosterones had no ef-
fect on H + -ATPase activity, suggesting specificity for al-
dosterone  [75, 76] .
 The receptor mediating the rapid effects of aldoste-
rone in intercalated cells is unknown. Interestingly, inhi-
bition of G αq  proteins or phospholipase C activity blocked 
the effects of aldosterone, suggesting that either G pro-
tein-coupled receptors (GPCRs) mediate the effects or 
that additional signals through a GPCR play a permissive 
role in aldosterone signaling.
 The MR may interact with epidermal growth factor 
receptor (EGFR) signaling by transactivation of EGFR-
dependent signaling cascades  [86] . Whether such a cross-
talk between MR and EGFR signaling is responsible for 
the rapid effects of aldosterone on H + -ATPase activity re-
mains to be examined.
 Injection of aldosterone in mice and rats caused a 
translocation of H + -ATPases to the luminal membrane 
with massive protrusion of the apical membrane indicat-
ing cellular remodeling and increased H + -ATPase den-
sity at the luminal membrane  [75, 76] . A similar stimula-
tion of H + -ATPase activity, translocation of H + -ATPases, 
and remodeling of intercalated cells is observed after di-
rect stimulation with PKA agonists  [87] . Indeed, block-
ade of PKA prevented the stimulatory effect of aldoste-
rone. Moreover, the signaling cascade involves rises in 
intracellular calcium, PKC and ERK1/2  [75, 76] .
 Indirect Regulation
 Aldosterone stimulates sodium reabsorption in the 
late DCT and collecting duct through the epithelial so-
dium channel ENaC expressed in principal cells  [88, 89] . 
Increased electrogenic sodium reabsorption renders the 
transepithelial potential in the collecting duct more nega-
tive in the lumen. This potential difference facilitates pro-
ton secretion by neighboring intercalated cells  [90] . Con-
sequently, blockade of ENaC channels with inhibitors 
such as amiloride or triamterene reduces urinary acidifi-
cation  [90] .
 The aldosterone stimulated urinary acidification de-
pending on ENaC activity forms the basis for a clinical 
test examining the ability of the connecting tubule and 
collecting duct to maximally acidify urine. This test is 
used in patients suspected to suffer from forms of incom-
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plete or complete distal renal tubular acidosis as an alter-
native for the classic ammonium chloride loading test 
that is often not well tolerated. Patients are given a com-
bination of mineralocorticoid analogues such as fludro-
cortisone to stimulate ENaC activity and a loop diuretic 
such as furosemide. Furosemide blocks the Na/K/2Cl –  
cotransporter NKCC2 in the TAL and delivers more so-
dium to downstream segments thereby increasing sodi-
um reabsorption by ENaC. In healthy subjects, urinary 
pH acidifies under such treatment below pH 5.4 whereas 
in patients with impaired distal urinary acidification uri-
nary pH remains more alkaline  [91, 92] .
 This crosstalk between principal cells and intercalated 
cells may be even more complex as indicated above. In 
type I distal renal tubular acidosis, due to mutations of 
AE1 or the a4 and B1 H + -ATPase subunits, urinary salt 
and potassium wasting has been described which is not 
fully reversed by correction of acidosis  [93, 94] . Experi-
ments in mice lacking the B1 H + -ATPase subunit dem-
onstrated an impaired ability to conserve NaCl and con-
centrate urine together with increased kaliuresis in view 
of elevated angiotensin II and aldosterone levels  [28] . 
Defective intercalated cells may secrete ATP, increase 
prostaglandin production and thereby signal to neigh-
boring principal cells where ENaC expression was re-
duced. Thus, potassium wasting in distal renal tubular 
acidosis may be at least in some patients caused by ele-
vated aldosterone levels in combination with direct in-
teractions between intercalated and principal cells  [28, 
94, 95] .
 Role of Aldosterone in Acid-Base Balance in CKD
 In animal models and patients with reduced kidney 
function, renal acidosis develops and may contribute to 
the further decline in renal function  [96–99] . In an ear-
lier stage of reduced nephron numbers, acid-base bal-
ance is maintained and may depend on elevated angio-
tensin II levels  [100] . In later stages of CKD (e.g. stage 4) 
enhanced aldosterone secretion may be promoted by 
stimulated endothelin production due to accumulation 
of acid in kidney and other tissues. Treatment of acidosis 
with alkali substitution reduces aldosterone in these pa-
tients  [98] . Blockade of MR appears to slow down the rate 
of loss of GFR in a rat model of CKD  [97] . How aldoste-
rone alone or in conjunction with acidosis and other fac-
tors contributes to decline of renal function is an open 
question.
 Summary and Outlook
 Aldosterone is a very powerful regulator of acid-base 
balance and links this important function to the regula-
tion of salt and potassium homeostasis. However, where-
as acidosis and volume depletion are associated with el-
evated angiotensin II levels, hyperkalemia is not. Angio-
tensin II has a very strong direct stimulatory effect on 
renal excretion and appears to have also a permissive ef-
fect on genomic effects of aldosterone in intercalated cells 
by dephosphorylating the MR. Aldosterone stimulates 
both type A intercalated cells increasing urinary acid ex-
cretion as well as non-type A intercalated cells leading to 
enhanced activity of pendrin. Depending on the coupling 
of type A and non-type A intercalated cells this may result 
either in increased acid secretion, alkali secretion or acid-
base neutral chloride reabsorption. However, the exact 
role of aldosterone and its interaction with other hor-
mones and factors are only partly understood. Along the 
same line, the mechanisms that increase aldosterone se-
cretion during acidosis are mostly unknown.
 The molecular mechanisms of the non-genomic rapid 
effects of aldosterone as well as their physiological rele-
vance are not fully explored. The effects occur in vitro and 
in vivo but whether it requires the MR or which other 
receptor(s) is/(are) involved has not answered. In view of 
the increasing number of non-genomic effects of steroid 
hormones, it is likely that aldosterone and other steroid 
hormones are able to activate alternative signaling routes 
 [101, 102] .
 In patients with CKD, the increased secretion of aldo-
sterone induced by the renal retention of acid may turn 
from a protective mechanism into a factor contributing 
to the progression of disease. Whether blockade of aldo-
sterone secretion or action, possibly in combination with 
neutralizing the acid overload, could be beneficial for pa-
tients with CKD remains to be shown.
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